Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
29 authors.
Dimitrios N SidiropoulosConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-5716-3917
Sarah M ShinConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-7658-5899
Meredith WetzelConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0005-6955-3521
Alexander A GirgisConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-4706-5480
Daniel BergmanConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-2166-6616
Ludmila DanilovaConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-2813-3094
Susheel PerikalaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0009-4558-6782
Daniel ShuConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-1348-5556
Janelle M MontagneConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-8113-1373
Atul DeshpandeConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-5144-6924
James LeathermanConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-1721-2128
Lucie DequiedtDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0006-1683-2161
Victoria JacobsDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0008-6188-7502
Aleksandra OgurtsovaDepartment of Pathology, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0007-3064-1780
Guanglan MoConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0003-6519-3675
Xuan YuanConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-7304-9927
Dmitrijs LvovsConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0009-0003-2152-6853
Genevieve Stein-O'BrienConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-8681-9110
Mark YarchoanConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-4401-0748
Qingfeng ZhuConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0001-7871-3359
Elizabeth I HarperDepartment of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.ORCID 0000-0002-3547-1692
Ashani T WeeraratnaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-0448-6952
Ashley L KiemenDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-6281-2616
Elizabeth M JaffeeConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-3841-6549
Lei ZhengConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-4163-2541
Won Jin HoConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-2644-5086
Robert A AndersConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-2363-9072
Elana J FertigConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-3204-342X
Luciane T KagoharaConvergence Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-1706-0950
Funding
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 1993 to 2022
$54.6M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI AMARAVADI, RAVI K · 2008 to 2023
$37.1M
Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A. · 2021 to 2025
$12.7M
Integrating bioinformatics into multiscale models for hepatocellular carcinomaU01CA212007 · NCI · JOHNS HOPKINS UNIVERSITY · PI EWALD, ANDREW JOSEF, FERTIG, ELANA · 2018 to 2022
$3.2M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Comprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975k
Resolving Spatiotemporal Determinants of Cell Specification in Corticogenesis with Latent Space MethodsR00NS122085 · NINDS · JOHNS HOPKINS UNIVERSITY · PI STEIN-O'BRIEN, GENEVIEVE LAUREN · 2023 to 2025
$697k
Integrative Analysis of the Aging Peritoneum in Metastatic ReceptivityK00AG068527 · NIA · JOHNS HOPKINS UNIVERSITY · PI HARPER, ELIZABETH · 2023 to 2025
$223k
Determining Dendritic Cell Responses to Vaccine-based Immunotherapy in PDAC at Single Cell Resolution.F31CA268724 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDIROPOULOS, DIMITRIOS N · 2022 to 2023
$67k
Allegheny Health Network (AHN)American Association for Cancer Research (AACR) SU2C/AACR DT-14-14Emerson Collective (Emerson)Lustgarten Foundation (Lustgarten)Mark Foundation For Cancer Research (The Mark Foundation for Cancer Research)National Cancer Institute (NCI) NCI F31CA268724-01National Cancer Institute (NCI) NCI R50 CA243627National Cancer Institute (NCI) NIH P01CA114046 (NCI)National Cancer Institute (NCI) NIH P01-CA247886-01A1National Cancer Institute (NCI) NIH U01CA212007National Cancer Institute (NCI) NIH U01CA253403National Cancer Institute (NCI) SPORE GI P50CA062924-24A1National Institute on Aging (NIA) NIH K00AG068527 (NIA)NCI NIH HHS F31 CA268724NCI NIH HHS P01 CA114046NCI NIH HHS P01 CA247886NCI NIH HHS P50 CA062924NCI NIH HHS R50 CA243627NCI NIH HHS U01 CA212007NCI NIH HHS U01 CA253403NIA NIH HHS K00 AG068527NINDS NIH HHS R00 NS122085Office of the Provost, Johns Hopkins University Discovery AwardSamuel Waxman Cancer Research Foundation (SWCRF)Sanofi (Sanofi US)Sol Goldman Charitable Trustl
6 · The paper itself
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a rapidly progressing cancer that responds poorly to immunotherapies. Intratumoral tertiary lymphoid structures (TLS) have been associated with rare long-term PDAC survivors, but the role of TLS in PDAC and their spatial relationships within the context of the broader tumor microenvironment remain unknown. In this study, we report the generation of a spatial multiomic atlas of PDAC tumors and tumor-adjacent lymph nodes from patients treated with combination neoadjuvant immunotherapies. Using machine learning-enabled hematoxylin and eosin image classification models, imaging mass cytometry, and unsupervised gene expression matrix factorization methods for spatial transcriptomics, we characterized cellular states within and adjacent to TLS spanning distinct spatial niches and pathologic responses. Unsupervised learning identified TLS-specific spatial gene expression signatures that are significantly associated with improved survival in patients with PDAC. We identified spatial features of pathologic immune responses, including intratumoral TLS-associated B-cell maturation colocalizing with IgG dissemination and extracellular matrix remodeling. Our findings offer insights into the cellular and molecular landscape of TLS in PDACs during immunotherapy treatment.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.